ArticleOncotarget2018

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

Lode J Swinnen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.